The European Pharmaceutical Wholesale Industry: - phagro

Contents
a
The European Pharmaceutical Wholesale Industry
EXECUTIVE SUMMARY......................................................................................................................I
1 INTRODUCTION ........................................................................................................................... 1
2 APPROACH AND METHODOLOGY......................................................................................... 3
3 THE ROLE OF THE PHARMACEUTICAL WHOLESALE INDUSTRY WITHIN THE
PHARMACEUTICAL SECTOR................................................................................................... 6
4 CORE INDICATORS OF THE PHARMACEUTICAL WHOLESALE INDUSTRY........... 10
4.1 MARKET STRUCTURE................................................................................................................. 10
4.2 SALES ........................................................................................................................................ 15
4.2.1 Influencing Factors on Wholesalers’ Sales........................................................................ 18
4.2.1.1 The Influence of Prices for “old” Pharmaceuticals and the Influence of the Development of
Wholesale Margins.................................................................................................................... 19
4.2.1.2 The Influence of Prices for “new” Pharmaceuticals ................................................................... 20
4.2.1.3 Structural Changes and Product Diversification......................................................................... 21
4.2.1.4 The Influence of the Level of Consumption............................................................................... 22
4.3 EMPLOYMENT............................................................................................................................ 23
5 THE MACROECONOMIC IMPACT OF THE PHARMACEUTICAL WHOLESALE
INDUSTRY .................................................................................................................................... 25
5.1 GENERATING VALUE ADDED..................................................................................................... 26
5.2 GENERATING EMPLOYMENT ...................................................................................................... 28
5.3 MULTIPLYING EFFECTS.............................................................................................................. 30
6 EFFICIENCY INDICATORS...................................................................................................... 33
6.1 BRINGING MEDICINES TO THE PATIENTS ................................................................................... 33
6.2 WHOLESALING: BENEFITS FOR THE PATIENT............................................................................. 39
6.3 PROCUREMENT, WAREHOUSING, AND DISTRIBUTION................................................................ 40
6.3.1 Procurement....................................................................................................................... 40
6.3.2 Warehousing ...................................................................................................................... 41
6.3.3 Distribution........................................................................................................................ 44
6.4 PRODUCTIVITY........................................................................................................................... 46
6.5 COMPARISON TO OTHER WHOLESALE INDUSTRIES .................................................................... 48
6.6 THE DISTRIBUTION CHAIN WITH AND WITHOUT WHOLESALERS................................................ 51
7 STRUCTURAL CHANGES IN PHARMACEUTICAL WHOLESALING............................ 54
8 FROM DISTRIBUTION TO KNOWLEDGE-INTENSIVE HEALTH CARE PROVISION61
ANNEX................................................................................................................................................... 64
INPUT-OUTPUT ANALYSIS.................................................................................................................... 64
BALIGH-RICHARTZ EFFECT.................................................................................................................. 67
IPF Institute for Pharmaeconomic Research